The following files are required for me to teach students appearing for the INI SS CET CVTS which is a single best answer multiple choice question examination. Generate 2 files from chapter 57 1. High yield notes from each chapter for teaching with probable questions. 2. 20 MCQs from chapter 57 in the INI CET SS format single best answer, can have a paragraph question. Do include image questions as well, images to be added in the PDF itself, with attribute from where it has been taken, source can be the internet as well. Make sure that the PDF has all 20 questions.
Reading File
Running Command
cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/d…
Running Command
cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/d…
Running Command
cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/d…
Running Command
cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/d…
Running Command
cd /home/daytona/workspace && python3 -c " from pypdf import PdfReader import os…
Running Command
ls /home/daytona/workspace/ch57_images/
Writing File
~/ch57_notes.py
#!/usr/bin/env python3
"""Generate High-Yield Notes PDF for Chapter 57 - Management of Acute Coronary Syndromes"""
from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm, mm
from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table,
TableStyle, HRFlowable, PageBreak, ListFlowable, ListItem)
from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY
from reportlab.platypus import KeepTogether
OUTPUT = '/home/daytona/workspace/Ch57_HighYield_Notes.pdf'
doc = SimpleDocTemplate(
OUTPUT,
pagesize=A4,
topMargin=2*cm, bottomMargin=2*cm,
leftMargin=2*cm, rightMargin=2*cm,
title='Chapter 57 High-Yield Notes – ACS Management',
author='INI SS CET CVTS Prep'
)
styles = getSampleStyleSheet()
# Custom styles
title_style = ParagraphStyle('Title', parent=styles['Title'],
fontSize=22, textColor=colors.HexColor('#1a237e'),
spaceAfter=6, alignment=TA_CENTER, fontName='Helvetica-Bold')
subtitle_style = ParagraphStyle('Subtitle', parent=styles['Normal'],
fontSize=12, textColor=colors.HexColor('#37474f'),
alignment=TA_CENTER, spaceAfter=12)
h1 = ParagraphStyle('H1', parent=styles['Heading1'],
fontSize=14, textColor=colors.white,
backColor=colors.HexColor('#1a237e'),
spaceBefore=14, spaceAfter=6,
leftIndent=-10, rightIndent=-10,
borderPad=6, fontName='Helvetica-Bold')
h2 = ParagraphStyle('H2', parent=styles['Heading2'],
fontSize=12, textColor=colors.HexColor('#1a237e'),
spaceBefore=10, spaceAfter=4,
borderPad=3, fontName='Helvetica-Bold',
borderWidth=0, leftIndent=0)
h3 = ParagraphStyle('H3', parent=styles['Heading3'],
fontSize=11, textColor=colors.HexColor('#880e4f'),
spaceBefore=8, spaceAfter=3,
fontName='Helvetica-Bold')
body = ParagraphStyle('Body', parent=styles['Normal'],
fontSize=10, leading=14, textColor=colors.HexColor('#212121'),
spaceAfter=4, alignment=TA_JUSTIFY)
bullet = ParagraphStyle('Bullet', parent=styles['Normal'],
fontSize=10, leading=13, textColor=colors.HexColor('#212121'),
leftIndent=14, spaceAfter=3, bulletIndent=0)
subbullet = ParagraphStyle('SubBullet', parent=styles['Normal'],
fontSize=9.5, leading=13, textColor=colors.HexColor('#37474f'),
leftIndent=28, spaceAfter=2, bulletIndent=14)
highlight = ParagraphStyle('Highlight', parent=styles['Normal'],
fontSize=10, leading=13, textColor=colors.HexColor('#212121'),
backColor=colors.HexColor('#fff9c4'),
leftIndent=10, rightIndent=10, spaceBefore=4, spaceAfter=4,
borderPad=4)
exam_tip = ParagraphStyle('ExamTip', parent=styles['Normal'],
fontSize=10, leading=13, textColor=colors.HexColor('#1b5e20'),
backColor=colors.HexColor('#e8f5e9'),
leftIndent=10, rightIndent=10, spaceBefore=4, spaceAfter=4,
borderPad=4, fontName='Helvetica-Bold')
def B(text):
return f'<b>{text}</b>'
def R(text):
return f'<font color="#c62828">{text}</font>'
def colored_box(text, bg='#e3f2fd', border='#1565c0'):
return ParagraphStyle('CB', parent=styles['Normal'],
fontSize=10, backColor=colors.HexColor(bg),
leftIndent=8, rightIndent=8, spaceBefore=4, spaceAfter=4, borderPad=4)
story = []
# ─── COVER ───────────────────────────────────────────────────────────────────
story.append(Spacer(1, 1*cm))
story.append(Paragraph('INI SS CET · CVTS', subtitle_style))
story.append(Paragraph('Chapter 57', subtitle_style))
story.append(Paragraph('Management of Acute Coronary Syndromes', title_style))
story.append(Paragraph('High-Yield Notes for Teaching', subtitle_style))
story.append(Paragraph('<i>Piana & Bagai | Sabiston & Spencer Surgery of the Chest, 9th Ed.</i>', subtitle_style))
story.append(HRFlowable(width='100%', thickness=2, color=colors.HexColor('#1a237e')))
story.append(Spacer(1, 0.5*cm))
# ─── SECTION 1: DEFINITIONS & CLASSIFICATION ─────────────────────────────────
story.append(Paragraph('1. DEFINITIONS & CLASSIFICATION', h1))
story.append(Spacer(1, 2*mm))
story.append(Paragraph(B('ACS Spectrum'), h2))
story.append(Paragraph('ACS = spectrum of conditions due to <b>abrupt reduction in coronary blood flow.</b>', body))
data = [
[Paragraph('<b>Type</b>', body), Paragraph('<b>Biomarkers</b>', body), Paragraph('<b>ECG</b>', body)],
[Paragraph('Unstable Angina (UA)', body), Paragraph('Normal', body), Paragraph('No ST elevation; ST depression / T inversion possible', body)],
[Paragraph('NSTEMI', body), Paragraph('Elevated (troponin)', body), Paragraph('No persistent ST elevation', body)],
[Paragraph('STEMI', body), Paragraph('Elevated (troponin)', body), Paragraph('New persistent ST elevation or new LBBB', body)],
]
t = Table(data, colWidths=[4.5*cm, 3.5*cm, 8*cm])
t.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1a237e')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#e8eaf6'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#9fa8da')),
('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
]))
story.append(t)
story.append(Spacer(1, 4*mm))
story.append(Paragraph(B('Type 1 vs Type 2 MI — KEY DISTINCTION'), h2))
data2 = [
[Paragraph('<b>Feature</b>', body), Paragraph('<b>Type 1 MI</b>', body), Paragraph('<b>Type 2 MI</b>', body)],
[Paragraph('Mechanism', body), Paragraph('Plaque disruption + thrombosis', body), Paragraph('Supply-demand mismatch', body)],
[Paragraph('Coronary thrombus', body), Paragraph('Present', body), Paragraph('Not required', body)],
[Paragraph('Troponin pattern', body), Paragraph('Rising/falling with ≥1 value >99th %ile URL', body), Paragraph('Same criteria', body)],
[Paragraph('Mortality', body), Paragraph('Lower than type 2', body), Paragraph('Higher (comorbidity burden)', body)],
[Paragraph('CAD on angiography', body), Paragraph('Common', body), Paragraph('Often present; portends worse prognosis', body)],
]
t2 = Table(data2, colWidths=[4*cm, 6*cm, 6*cm])
t2.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#880e4f')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#fce4ec'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#f48fb1')),
('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
]))
story.append(t2)
story.append(Spacer(1, 4*mm))
story.append(Paragraph('⚡ <b>EXAM TIP:</b> Type 2 MI patients have <b>HIGHER</b> overall mortality than type 1 MI due to greater comorbidity burden, despite lower cardiac risk per se.', exam_tip))
story.append(Spacer(1, 2*mm))
# ─── SECTION 2: PATHOPHYSIOLOGY ──────────────────────────────────────────────
story.append(Paragraph('2. PATHOPHYSIOLOGY', h1))
story.append(Paragraph(B('Plaque Rupture vs Erosion'), h2))
story.append(Paragraph('• <b>Thin Cap FibroAtheroma (TCFA)</b> = "vulnerable plaque" → most common precipitant of ACS.', bullet))
story.append(Paragraph('• Fibrous cap thinned by: matrix metalloproteinases, SMC apoptosis, plaque hemorrhage.', bullet))
story.append(Paragraph('• <b>Plaque rupture</b>: older, male, greater stenosis, calcification, macrophage infiltration.', bullet))
story.append(Paragraph('• <b>Plaque erosion</b>: superficial erosion of proteoglycan/SMC-rich lesions (less advanced).', bullet))
story.append(Spacer(1, 2*mm))
story.append(Paragraph(B('Platelet Activation Cascade'), h2))
steps = [
'Vascular injury → exposure of <b>collagen + vWF</b>',
'Platelet adhesion → monolayer formation on collagen matrix',
'Release of <b>ADP, TxA2, serotonin</b> from platelet granules',
'Platelet recruitment + shape change + GP IIb/IIIa receptor activation',
'Cross-linking via <b>fibrinogen</b> binding to active GP IIb/IIIa',
'<b>Thrombin</b> (most potent activator) generated by tissue factor from eroded plaque → fibrin formation',
'Cross-linked platelets + fibrin → occlusive/sub-occlusive thrombus',
]
for i, s in enumerate(steps, 1):
story.append(Paragraph(f'{i}. {s}', bullet))
story.append(Spacer(1, 2*mm))
story.append(Paragraph('⚡ <b>EXAM TIP:</b> GP IIb/IIIa = <b>final common pathway</b> of platelet aggregation regardless of mode of activation. ~50,000 copies per platelet.', exam_tip))
story.append(Spacer(1, 2*mm))
story.append(Paragraph(B('Type 2 MI Causes: Supply-Demand Mismatch'), h2))
data3 = [
[Paragraph('<b>Increased Demand</b>', body), Paragraph('<b>Decreased Supply</b>', body)],
[Paragraph('Tachycardia (infection, thyrotoxicosis, arrhythmia)\nSevere hypertension\nSevere aortic stenosis\nHypertrophic cardiomyopathy', body),
Paragraph('Fixed coronary obstruction (atherosclerosis)\nDrug/toxin-induced vasospasm\nMicrovascular dysfunction\nMyocardial bridging\nBradyarrhythmia, hypotension/shock\nRespiratory failure, severe anemia/blood loss', body)],
]
t3 = Table(data3, colWidths=[8*cm, 8*cm])
t3.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#4a148c')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#ede7f6')]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#b39ddb')),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 5),
('BOTTOMPADDING', (0,0), (-1,-1), 5),
]))
story.append(t3)
story.append(Spacer(1, 4*mm))
# ─── SECTION 3: DIAGNOSIS ──────────────────────────────────────────────────
story.append(Paragraph('3. DIAGNOSIS', h1))
story.append(Paragraph(B('ECG Criteria'), h2))
story.append(Paragraph('<b>STEMI criteria (ST elevation at J point in ≥2 contiguous leads):</b>', body))
story.append(Paragraph('• ≥1 mm in all leads except V2–V3', bullet))
story.append(Paragraph('• V2–V3: ≥2 mm in men ≥40 yr; ≥2.5 mm in men <40 yr; ≥1.5 mm in women (any age)', bullet))
story.append(Paragraph('• New LBBB in context of ischemic symptoms = STEMI equivalent', bullet))
story.append(Spacer(1, 2*mm))
ecg_data = [
[Paragraph('<b>ECG Pattern</b>', body), Paragraph('<b>Significance</b>', body)],
[Paragraph('ST depression ≥0.5 mm in ≥2 contiguous leads', body), Paragraph('NSTEMI/UA — acute ischemia', body)],
[Paragraph('T-inversion >1 mm in ≥2 contiguous leads with prominent R or R/S>1', body), Paragraph('Acute ischemia (not LVH/BBB)', body)],
[Paragraph('ST depression ≥1 mm in 6 leads + ST elevation in aVR or V1', body), Paragraph('Multivessel/Left main disease', body)],
[Paragraph('Deeply inverted/biphasic T waves (initial positivity) V2–V3 + isoelectric ST', body), Paragraph("Wellens' syndrome — critical proximal LAD stenosis", body)],
[Paragraph('Tall symmetric T waves + upsloping ST depression >1 mm at J point in precordial leads', body), Paragraph("de Winter's pattern — acute proximal LAD occlusion", body)],
[Paragraph('Horizontal ST depression V1–V3 (posterior injury current)', body), Paragraph('Transmural posterior STEMI', body)],
]
tecg = Table(ecg_data, colWidths=[9*cm, 7*cm])
tecg.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#004d40')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#e0f2f1'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#80cbc4')),
('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
]))
story.append(tecg)
story.append(Spacer(1, 3*mm))
story.append(Paragraph(B('Cardiac Biomarkers'), h2))
story.append(Paragraph('• Preferred: <b>cardiac Troponins (cTnT, cTnI)</b> — most sensitive & specific for myocardial necrosis.', bullet))
story.append(Paragraph('• Draw at presentation and <b>3–6 hours after symptom onset</b> (rising/falling pattern required).', bullet))
story.append(Paragraph('• cTnT less specific than cTnI — can rise in skeletal muscle disease.', bullet))
story.append(Paragraph('• CPK-MB: less sensitive, lower specificity; <b>NOT recommended</b> by current guidelines for early detection.', bullet))
story.append(Paragraph('• Elevated cTn = myocardial necrosis but is NOT specific for an ischemic etiology.', bullet))
story.append(Spacer(1, 2*mm))
story.append(Paragraph(B('Risk Scores'), h2))
risk_data = [
[Paragraph('<b>Score</b>', body), Paragraph('<b>Components</b>', body), Paragraph('<b>Predicts</b>', body)],
[Paragraph('HEART Score', body), Paragraph('History, ECG, Age, Risk factors, Troponin\n(includes physician judgment)', body), Paragraph('30-day death/MI; superior for initial ED screening\n<3: 0.2%; 4–6: 1%; 7–10: 3%', body)],
[Paragraph('TIMI (NSTEMI)', body), Paragraph('7 variables including age, CAD risk, ST change, biomarker', body), Paragraph('14-day outcomes', body)],
[Paragraph('GRACE', body), Paragraph('Age, HR, BP, creatinine, Killip, biomarkers', body), Paragraph('6-month outcomes; >140 = high risk for early invasive benefit', body)],
[Paragraph('TIMI (STEMI)', body), Paragraph('Killip class, BP, HR, age, weight, Killip\nRisk index = HR × (Age/10)² / SBP', body), Paragraph('30-day mortality; >40-fold gradient from score 0→>8', body)],
[Paragraph('SYNTAX Score', body), Paragraph('Complexity/extent of CAD on angiography', body), Paragraph('Guides PCI vs CABG; >32 favors CABG', body)],
]
trisk = Table(risk_data, colWidths=[3.5*cm, 7*cm, 5.5*cm])
trisk.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#bf360c')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#fbe9e7'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#ff8a65')),
('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
]))
story.append(trisk)
story.append(Spacer(1, 4*mm))
# ─── SECTION 4: PHARMACOLOGIC MANAGEMENT ──────────────────────────────────────
story.append(Paragraph('4. PHARMACOLOGIC MANAGEMENT', h1))
story.append(Paragraph(B('Anti-Ischemic Therapy'), h2))
anti_data = [
[Paragraph('<b>Drug</b>', body), Paragraph('<b>Class I (Do)</b>', body), Paragraph('<b>Class III (Avoid)</b>', body)],
[Paragraph('IV Nitroglycerin', body), Paragraph('48h for persistent ischemia, HF, or HTN', body), Paragraph('SBP <90; RV infarction; PDE-5i within 24h (sildenafil/vardenafil) or 48h (tadalafil)', body)],
[Paragraph('Oral Beta-Blockers', body), Paragraph('Start within 24h if no CI;\nOnly metoprolol/bisoprolol/carvedilol (long-acting) for LVEF <40%', body), Paragraph('Any CHF signs; low output; cardiogenic shock risk; advanced conduction disease; active asthma', body)],
[Paragraph('Oral ACEI', body), Paragraph('Within 24h if pulm congestion or LVEF <40%;\nARB if ACEI intolerant (no angioedema history)', body), Paragraph('SBP <100; do NOT give IV ACEI in first 24h', body)],
[Paragraph('Non-DHP CCB\n(verapamil, diltiazem)', body), Paragraph('Ongoing ischemia when beta-blockers contraindicated', body), Paragraph('LV dysfunction; shock risk; PR >0.24s; 2°/3° AVB without pacemaker', body)],
[Paragraph('NSAIDs / COX-2i', body), Paragraph('NOT indicated', body), Paragraph('Increased risk of MI rupture, CHF, reinfarction, MACE — CONTRAINDICATED', body)],
]
tant = Table(anti_data, colWidths=[3.5*cm, 6*cm, 6.5*cm])
tant.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#006064')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#e0f7fa'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#4dd0e1')),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
]))
story.append(tant)
story.append(Spacer(1, 4*mm))
story.append(Paragraph(B('Antiplatelet Therapy'), h2))
story.append(Paragraph('<b>Aspirin:</b>', h3))
story.append(Paragraph('• Irreversibly inhibits <b>COX-1</b> → prevents TxA2 formation.', bullet))
story.append(Paragraph('• Loading: <b>162–325 mg</b> non-enteric coated chewable; Maintenance: <b>81 mg/day</b> (current preferred).', bullet))
story.append(Paragraph('• Minimum effective dose: 75 mg (22% reduction in vascular death/MI/stroke).', bullet))
story.append(Paragraph('• Doses >200 mg: increased bleeding WITHOUT additional anti-thrombotic benefit.', bullet))
story.append(Spacer(1, 2*mm))
story.append(Paragraph('<b>P2Y12 Inhibitors — Comparison:</b>', h3))
p2y12_data = [
[Paragraph('<b>Drug</b>', body), Paragraph('<b>Mechanism</b>', body), Paragraph('<b>Loading</b>', body), Paragraph('<b>Maintenance</b>', body), Paragraph('<b>Key Points</b>', body)],
[Paragraph('Clopidogrel', body), Paragraph('Prodrug; 2-step activation via CYP2C19', body), Paragraph('300–600 mg', body), Paragraph('75 mg/day', body), Paragraph('CYP2C19 polymorphism → variable response; *2,*3 alleles = HTPR; *17 = hyperresponder', body)],
[Paragraph('Prasugrel', body), Paragraph('Prodrug; 1-step activation; NOT CYP2C19 dependent', body), Paragraph('60 mg', body), Paragraph('10 mg/day (5 mg if <60 kg)', body), Paragraph('ONLY after defining coronary anatomy; CI: prior stroke/TIA, active bleeding, age >75 generally avoided', body)],
[Paragraph('Ticagrelor', body), Paragraph('Reversible, non-competitive P2Y12 antagonist; NO hepatic activation', body), Paragraph('180 mg', body), Paragraph('90 mg BD', body), Paragraph('85–95% platelet inhibition in 2h; higher mortality benefit (PLATO); avoid aspirin >100 mg concurrently', body)],
[Paragraph('Cangrelor', body), Paragraph('IV ATP analogue; reversible competitive P2Y12 inhibitor', body), Paragraph('IV bolus pre-PCI', body), Paragraph('Infusion ≥2h or duration of PCI', body), Paragraph('Half-life 3–6 min; full platelet recovery in 60 min; inhibits binding of clopidogrel/prasugrel active metabolites — give loading AFTER cangrelor infusion', body)],
]
tp2y = Table(p2y12_data, colWidths=[2.5*cm, 3.5*cm, 2*cm, 2.5*cm, 5.5*cm])
tp2y.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#e65100')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#fff3e0'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#ffb74d')),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
('FONTSIZE', (0,1), (-1,-1), 9),
]))
story.append(tp2y)
story.append(Spacer(1, 3*mm))
story.append(Paragraph('⚡ <b>EXAM TIPS — P2Y12 Inhibitors:</b>', exam_tip))
story.append(Paragraph('• ISAR-REACT 5: Prasugrel superior to ticagrelor at 1 year in ACS patients undergoing PCI (comparable bleeding).', bullet))
story.append(Paragraph('• Prasugrel: 3 "No Net Benefit / Harm" subgroups — age >75, weight <60 kg, prior stroke/TIA.', bullet))
story.append(Paragraph('• DAPT duration: 12 months for clopidogrel/ticagrelor (both invasive and conservative); prasugrel only if PCI performed.', bullet))
story.append(Paragraph('• Stop DAPT at 6 months: high bleeding risk OR surgery with high bleeding risk (continue low-dose aspirin).', bullet))
story.append(Spacer(1, 4*mm))
story.append(Paragraph('<b>GP IIb/IIIa Inhibitors (GPIs):</b>', h3))
story.append(Paragraph('• Available: <b>eptifibatide, tirofiban</b> (t½ = 2–3 h; IV infusion 12–18 h post-PCI). Abciximab no longer marketed in US.', bullet))
story.append(Paragraph('• GP IIb/IIIa = final common pathway of platelet aggregation (~50,000 receptors/platelet).', bullet))
story.append(Paragraph('• GPI effect NOT reversible by platelet transfusion.', bullet))
story.append(Paragraph('• Platelet aggregation inhibition falls to ~50% after 4h of discontinuation.', bullet))
story.append(Paragraph('• <b>Class I:</b> GPI at time of PCI with stenting if not pretreated with clopidogrel AND not on bivalirudin.', bullet))
story.append(Paragraph('• <b>Class IIa:</b> GPI in high-risk patients adequately pretreated with clopidogrel.', bullet))
story.append(Paragraph('• <b>Class IIb:</b> GPI addition to aspirin + P2Y12 in high-risk (elevated troponin) patients, early invasive strategy.', bullet))
story.append(Paragraph('• NO role in NSTE-ACS managed with initial ischemia-guided strategy.', bullet))
story.append(Spacer(1, 4*mm))
story.append(Paragraph(B('Antithrombotic (Anticoagulant) Therapy'), h2))
ac_data = [
[Paragraph('<b>Agent</b>', body), Paragraph('<b>Mechanism</b>', body), Paragraph('<b>Key Points</b>', body)],
[Paragraph('UFH', body), Paragraph('Binds antithrombin → inactivates IIa & Xa\n(>18 oligo chains inactivate IIa; shorter chains only Xa)', body), Paragraph('Half-life ~60 min (100 U/kg dose); equal anti-IIa and anti-Xa activity; cleared first by endothelial cells', body)],
[Paragraph('Enoxaparin (LMWH)', body), Paragraph('Anti-Xa > anti-IIa activity', body), Paragraph('SYNERGY trial: superior to UFH; do NOT switch between agents (increased bleeding); delay sheath removal 4–6h after IV dose, 6–8h after SQ', body)],
[Paragraph('Fondaparinux', body), Paragraph('Synthetic factor Xa inhibitor\nPentasaccharide sequence', body), Paragraph('2.5 mg SQ OD; non-inferior to enoxaparin but 3× guide catheter thrombus — MUST add anti-IIa agent (UFH/bivalirudin) if PCI performed', body)],
[Paragraph('Bivalirudin', body), Paragraph('Direct thrombin inhibitor', body), Paragraph('ISAR-REACT 4: bivalirudin vs UFH+abciximab — similar MACE, less bleeding; benefit less clear with radial access + potent P2Y12 use (modern practice)', body)],
]
tac = Table(ac_data, colWidths=[3*cm, 5.5*cm, 7.5*cm])
tac.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1a237e')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#e8eaf6'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#9fa8da')),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
('FONTSIZE', (0,1), (-1,-1), 9),
]))
story.append(tac)
story.append(Spacer(1, 3*mm))
story.append(Paragraph('⚡ <b>EXAM TIP — Fondaparinux at PCI:</b> Always add UFH or bivalirudin (anti-IIa activity) if PCI is performed on fondaparinux to prevent catheter thrombosis.', exam_tip))
story.append(Spacer(1, 3*mm))
story.append(Paragraph('<b>Vorapaxar (PAR-1 Antagonist):</b>', h3))
story.append(Paragraph('• Blocks thrombin-mediated platelet activation via PAR-1, preserving cleavage of fibrinogen to fibrin.', bullet))
story.append(Paragraph('• TRACER trial: with NSTE-ACS — significant ↑ moderate/severe bleeding (7.2% vs 5.2%) & 3× intracranial hemorrhage; no significant ↓ ischemic endpoint.', bullet))
story.append(Paragraph('• CABG patients on vorapaxar in TRACER trial: 45% lower rate of composite death/MI/stroke/ischemia during index hospitalization.', bullet))
story.append(Spacer(1, 3*mm))
story.append(Paragraph('<b>Oral Anticoagulants + ACS / Triple Therapy:</b>', h3))
story.append(Paragraph('• Triple therapy (DAPT + OAT): >2× risk of major bleeding vs DAPT alone (OR 2.12).', bullet))
story.append(Paragraph('• AUGUSTUS trial: Apixaban + P2Y12 inhibitor (without aspirin) → less bleeding vs warfarin regimen.', bullet))
story.append(Paragraph('• Current preferred strategy: <b>DOAC + P2Y12 inhibitor</b> (omit aspirin) — less bleeding, comparable MACE.', bullet))
story.append(Spacer(1, 4*mm))
# ─── SECTION 5: INVASIVE MANAGEMENT ──────────────────────────────────────────
story.append(Paragraph('5. INVASIVE MANAGEMENT OF NSTE-ACS', h1))
story.append(Paragraph(B('Early Invasive vs Ischemia-Guided Strategy'), h2))
inv_data = [
[Paragraph('<b>Early Invasive Strategy</b>', body), Paragraph('<b>Ischemia-Guided Strategy</b>', body)],
[Paragraph('• Urgent/immediate: refractory angina, hemodynamic/electrical instability\n• Early (within 24h): stabilized high-risk patients\n• High-risk criteria: recurrent angina, ↑troponin, new ST depression, HF/↑MR, high-risk noninvasive test, hemodynamic instability, sustained VT, PCI within 6mo, prior CABG, TIMI/GRACE high risk, LVEF <40%', body),
Paragraph('• Low TIMI score (0–1) or GRACE <109\n• Low-risk cTn-negative women\n• Patient/physician preference\n• Extensive comorbidities (liver/lung failure, cancer)\n• Angiography reserved for recurrent rest angina, positive stress test, or high-risk scores', body)],
]
tinv = Table(inv_data, colWidths=[8*cm, 8*cm])
tinv.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1b5e20')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#e8f5e9')]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#81c784')),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 5),
('BOTTOMPADDING', (0,0), (-1,-1), 5),
]))
story.append(tinv)
story.append(Spacer(1, 3*mm))
story.append(Paragraph('• <b>TIMACS trial:</b> Early (≤24h) vs delayed (≥36h) — no overall benefit, BUT in highest-risk patients (GRACE >140), early intervention reduced ischemic events by <b>35%</b>.', bullet))
story.append(Paragraph('• Meta-analysis: Mortality reduced with early invasive therapy, but only in highest-risk patients (elevated biomarkers, DM, GRACE >140, age ≥75).', bullet))
story.append(Paragraph('• <b>ISAR-COOL trial:</b> Prolonged "cooling off" (>72h) not effective in high-risk patients; may cause harm.', bullet))
story.append(Spacer(1, 3*mm))
story.append(Paragraph(B('NSTE-ACS Surgical Considerations'), h2))
story.append(Paragraph('• Stop clopidogrel/ticagrelor ≥<b>5 days</b> before elective CABG.', bullet))
story.append(Paragraph('• Stop prasugrel ≥<b>7 days</b> before elective CABG.', bullet))
story.append(Paragraph('• If urgent CABG: discontinue clopidogrel/ticagrelor ≥24h; stop GPI (tirofiban/eptifibatide) ≥2–4h before CABG.', bullet))
story.append(Paragraph('• ~1/3 of NSTEMI patients undergo CABG within 48h (median 73h after admission).', bullet))
story.append(Paragraph('• In-hospital mortality: early (<48h) vs late (>48h) CABG — similar ~3.7%.', bullet))
story.append(Paragraph('• Operative mortality in >80 yr age: 5–8%; urgent cases 11%.', bullet))
story.append(Spacer(1, 3*mm))
story.append(Paragraph(B('Multivessel CAD — PCI vs CABG'), h2))
story.append(Paragraph('• "Heart team" approach: interventional cardiologist + cardiac surgeon.', bullet))
story.append(Paragraph('• SYNTAX score guides decision: <b>intermediate (22–32)</b> and <b>high (>32) = CABG preferred</b>.', bullet))
story.append(Paragraph('• CABG preferred in DM, CKD, depressed LV systolic function, complex multivessel disease.', bullet))
story.append(Spacer(1, 4*mm))
# ─── SECTION 6: STEMI ──────────────────────────────────────────────────────
story.append(Paragraph('6. STEMI MANAGEMENT', h1))
story.append(Paragraph(B('Reperfusion Therapy Selection'), h2))
rep_data = [
[Paragraph('<b>Reperfusion</b>', body), Paragraph('<b>Indications</b>', body), Paragraph('<b>Time Target</b>', body)],
[Paragraph('Primary PCI (preferred)', body),
Paragraph('Symptom onset <12h\nFibrinolysis contraindicated\nCardiogenic shock\nPCI-capable center available', body),
Paragraph('FMC to balloon:\n≤90 min (PCI-capable hospital)\n≤120 min (if transfer needed)', body)],
[Paragraph('Fibrinolysis', body),
Paragraph('No PCI within 120 min of FMC\nSymptoms <12h (Class I)\nSymptoms 12–24h with ongoing ischemia (Class I)\nShould be given within 10 min of ECG diagnosis', body),
Paragraph('Administer within 10 min of STEMI diagnosis', body)],
]
trep = Table(rep_data, colWidths=[3.5*cm, 9*cm, 3.5*cm])
trep.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#b71c1c')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#ffebee'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#ef9a9a')),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 5),
('BOTTOMPADDING', (0,0), (-1,-1), 5),
]))
story.append(trep)
story.append(Spacer(1, 3*mm))
story.append(Paragraph(B('Primary PCI — Key Points'), h2))
story.append(Paragraph('• Generally restricted to <b>infarct-related artery</b>, EXCEPT hemodynamic compromise from significant non-culprit stenosis.', bullet))
story.append(Paragraph('• <b>Complete revascularization</b> of non-culprit lesions (immediate multivessel PCI or staged PCI during hospitalization/within 6 weeks) = reduced MACE (2015 STEMI guideline update: Class III→Class IIb).', bullet))
story.append(Paragraph('• 12–24h after symptom onset with ongoing ischemia/hemodynamic instability/malignant arrhythmias: PCI still indicated.', bullet))
story.append(Paragraph('• Delayed PCI of totally occluded infarct artery >24h after STEMI in stable patients without ischemia: <b>NOT indicated (Class III)</b>.', bullet))
story.append(Spacer(1, 3*mm))
story.append(Paragraph(B('Fibrinolysis'), h2))
story.append(Paragraph('• Agents: <b>Tenecteplase (TNK-tPA)</b> single weight-based bolus; <b>Reteplase</b> two 10-unit IV boluses 30 min apart.', bullet))
story.append(Paragraph('• Both restore TIMI 2/3 flow in ~<b>85%</b> of patients.', bullet))
story.append(Paragraph('• Pre-hospital fibrinolysis: 17% reduction in all-cause mortality vs hospital-based.', bullet))
story.append(Paragraph('• <b>Failed reperfusion:</b> <50% ST-segment resolution in worst lead by 60–90 min → Rescue PCI (Class IIa).', bullet))
story.append(Paragraph('• <b>Pharmacoinvasive strategy:</b> Fibrinolysis → routine transfer for early (>3h and <24h) coronary angiography.', bullet))
story.append(Spacer(1, 3*mm))
story.append(Paragraph('<b>Absolute Contraindications to Fibrinolysis:</b>', h3))
fi_ci = [
'Prior intracranial hemorrhage',
'Known cerebral vascular lesion or neoplasm',
'Ischemic stroke within 3 months (except acute ischemic stroke <4.5h)',
'Intracranial/spinal surgery within 2 months',
'Closed head/facial trauma within 3 months',
'Suspected aortic dissection',
'Severe uncontrolled hypertension',
'Active bleeding or bleeding diathesis',
]
for item in fi_ci:
story.append(Paragraph(f'• {item}', bullet))
story.append(Spacer(1, 3*mm))
story.append(Paragraph(B('CABG in STEMI'), h2))
story.append(Paragraph('<b>Class I indications for urgent CABG in STEMI:</b>', body))
story.append(Paragraph('• Ongoing/recurrent ischemia not amenable to PCI', bullet))
story.append(Paragraph('• Failed PCI attempt in occluded major epicardial artery', bullet))
story.append(Paragraph('• Cardiogenic shock, severe HF, other high-risk features', bullet))
story.append(Paragraph('• During operative repair of mechanical complications (MR, VSD, free wall rupture)', bullet))
story.append(Paragraph('• Occluded coronary not amenable to PCI → CABG within hours (not days).', bullet))
story.append(Spacer(1, 4*mm))
# ─── SECTION 7: CARDIOGENIC SHOCK ────────────────────────────────────────────
story.append(Paragraph('7. CARDIOGENIC SHOCK IN ACS', h1))
story.append(Paragraph('• <b>Definition:</b> SBP <90 mmHg for ≥30 min OR supportive measures needed to maintain SBP ≥90 mmHg + end-organ hypoperfusion.', bullet))
story.append(Paragraph('• Incidence: <b>8.6%</b> of STEMI (NRMI database).', bullet))
story.append(Paragraph('• Typically when ≥<b>40%</b> of myocardium involved, OR mechanical complication (papillary muscle, VSD, free wall rupture).', bullet))
story.append(Paragraph('• <b>Multivessel CAD present in ~80%</b> of cardiogenic shock patients.', bullet))
story.append(Paragraph('• <b>SHOCK trial:</b> Mechanical revascularization (PCI or CABG) → improved 6- and 12-month survival vs fibrinolytic therapy.', bullet))
story.append(Paragraph('• Emergency revascularization (PCI or CABG) regardless of time delay from MI onset — recommended in cardiogenic shock.', bullet))
story.append(Paragraph('• CULPRIT-SHOCK trial concept: Ongoing trial data on PCI strategies in multivessel CAD with CS.', bullet))
story.append(Spacer(1, 4*mm))
# ─── SECTION 8: RADIAL ACCESS & POST-REVASCULARIZATION ───────────────────────
story.append(Paragraph('8. ADDITIONAL CONSIDERATIONS', h1))
story.append(Paragraph(B('Radial Access for PCI'), h2))
story.append(Paragraph('• Multiple trials show: radial access reduces major bleeding vs femoral in ACS.', bullet))
story.append(Paragraph('• <b>SAFARI-STEMI trial:</b> No difference in survival/MACE at 30 days (radial vs femoral, ~90% bivalirudin) — trial halted early for futility.', bullet))
story.append(Paragraph('• Bivalirudin benefit for bleeding reduction seen primarily with femoral access; radial access lowers bleeding with heparin.', bullet))
story.append(Paragraph('• Operators should maintain proficiency at both approaches.', bullet))
story.append(Spacer(1, 3*mm))
story.append(Paragraph(B('Secondary Prevention After ACS'), h2))
story.append(Paragraph('• <b>Cornerstone:</b> Antiplatelet agents + beta-blockers + statins.', bullet))
story.append(Paragraph('• ACEI/ARB/aldosterone antagonists: for HF, LVEF <40%, or DM.', bullet))
story.append(Paragraph('• High-dose atorvastatin: reduced composite death/stroke/MI/UA/revascularization from 30 days onward.', bullet))
story.append(Paragraph('• LDL target: <100 mg/dL (traditionally); added benefit with LDL <70 mg/dL in several trials.', bullet))
story.append(Paragraph('• <b>PCSK9 inhibitors</b> (alirocumab - ODYSSEY OUTCOMES): further reduce adverse outcomes post-ACS when added to statin.', bullet))
story.append(Spacer(1, 3*mm))
story.append(Paragraph(B('ICD After STEMI'), h2))
story.append(Paragraph('• ICD for primary SCD prevention if: persistent LVEF ≤30% (any class) OR LVEF ≤35% with NYHA class II+, persisting >90 days after revascularization.', bullet))
story.append(Paragraph('• Wearable Cardioverter-Defibrillator (WCD): sometimes used during first 90 days.', bullet))
story.append(Paragraph('• <b>VEST trial:</b> Prophylactic WCD in LVEF ≤35% post-MI did <b>NOT</b> reduce sudden death at 90 days.', bullet))
story.append(Spacer(1, 4*mm))
# ─── SECTION 9: KEY TRIALS SUMMARY ───────────────────────────────────────────
story.append(Paragraph('9. KEY CLINICAL TRIALS QUICK REFERENCE', h1))
trials_data = [
[Paragraph('<b>Trial</b>', body), Paragraph('<b>Question</b>', body), Paragraph('<b>Result / Bottom Line</b>', body)],
[Paragraph('TRITON-TIMI 38', body), Paragraph('Prasugrel vs clopidogrel in ACS', body), Paragraph('Prasugrel: fewer MI, stent thrombosis; more bleeding; NO net benefit: age>75, <60kg, prior stroke/TIA', body)],
[Paragraph('PLATO', body), Paragraph('Ticagrelor vs clopidogrel in ACS', body), Paragraph('Ticagrelor: lower mortality, MI, stent thrombosis; no overall major bleeding increase; avoid aspirin >100 mg', body)],
[Paragraph('ISAR-REACT 5', body), Paragraph('Prasugrel vs ticagrelor in ACS + PCI', body), Paragraph('Prasugrel superior at 1 year (2.4% absolute ↓ in death/MI/stroke); comparable bleeding', body)],
[Paragraph('SYNERGY', body), Paragraph('Enoxaparin vs UFH in high-risk ACS', body), Paragraph('Enoxaparin: lower death+MI; do not switch anticoagulants', body)],
[Paragraph('OASIS', body), Paragraph('Fondaparinux vs enoxaparin in UA/NSTEMI', body), Paragraph('Non-inferior efficacy; 1.9% less major bleeding; but 3× guide catheter thrombus at PCI → add anti-IIa', body)],
[Paragraph('SHOCK', body), Paragraph('Revascularization vs fibrinolysis in CS', body), Paragraph('PCI/CABG: improved 6- and 12-month survival in cardiogenic shock', body)],
[Paragraph('CHAMPION PHOENIX', body), Paragraph('Cangrelor vs clopidogrel at PCI', body), Paragraph('Cangrelor: 22% lower ischemic events; OR 0.78; no increase in severe bleeding', body)],
[Paragraph('TIMACS', body), Paragraph('Early (≤24h) vs delayed (≥36h) invasive in ACS', body), Paragraph('Overall no difference; in GRACE >140: 35% reduction in ischemic events with early strategy', body)],
[Paragraph('ACUITY', body), Paragraph('Bivalirudin vs heparin+GPI at PCI', body), Paragraph('Bivalirudin: improved NACE vs heparin+GPI; lower bleeding', body)],
[Paragraph('AUGUSTUS', body), Paragraph('Apixaban vs warfarin + P2Y12 (no ASA) in ACS+AF', body), Paragraph('Apixaban: less bleeding; adding aspirin significantly increased bleeding regardless of OAT choice', body)],
[Paragraph('TRACER', body), Paragraph('Vorapaxar vs placebo in NSTE-ACS', body), Paragraph('3× intracranial hemorrhage; nonsignificant ↓ ischemia; PAR-1 inhibition not suitable for NSTE-ACS', body)],
[Paragraph('VEST', body), Paragraph('Wearable ICD in LVEF ≤35% post-MI', body), Paragraph('Prophylactic WCD did NOT reduce sudden death at 90 days', body)],
[Paragraph('MATRIX', body), Paragraph('Bivalirudin vs UFH in 7213 ACS patients (56% STEMI)', body), Paragraph('Bivalirudin: lower all-cause/cardiac mortality + major bleeding; higher stent thrombosis', body)],
]
ttrials = Table(trials_data, colWidths=[4*cm, 5.5*cm, 6.5*cm])
ttrials.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,0), colors.HexColor('#263238')),
('TEXTCOLOR', (0,0), (-1,0), colors.white),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#eceff1'), colors.white]),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#90a4ae')),
('VALIGN', (0,0), (-1,-1), 'TOP'),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
('FONTSIZE', (0,1), (-1,-1), 9),
]))
story.append(ttrials)
story.append(Spacer(1, 4*mm))
# ─── SECTION 10: PROBABLE EXAM QUESTIONS ──────────────────────────────────────
story.append(Paragraph('10. PROBABLE EXAMINATION QUESTIONS', h1))
pq = [
('Q1', 'Which pattern on ECG in a patient with recent chest pain is highly specific for critical stenosis of the proximal LAD?',
"Wellens' syndrome — deeply inverted or biphasic T-waves (initial positivity) in V2–V3 with isoelectric/minimally elevated ST segments."),
('Q2', 'A 78-year-old female develops STEMI. Which P2Y12 inhibitor is preferred and what are the key precautions?',
'Ticagrelor (or clopidogrel) is preferred; prasugrel generally avoided in age >75 (no net benefit). If prasugrel used in this age group, weight <60 kg and prior stroke/TIA are absolute contraindications.'),
('Q3', 'What is the recommended FMC-to-balloon time for primary PCI in STEMI at a PCI-capable hospital vs transfer?',
'≤90 minutes at a PCI-capable hospital; ≤120 minutes when transfer to PCI-capable hospital is required.'),
('Q4', 'A patient with NSTEMI on fondaparinux undergoes PCI. What must be added and why?',
'An anti-IIa agent (UFH or bivalirudin) must be added to prevent guide catheter thrombosis, as fondaparinux lacks anti-IIa activity (3× higher incidence of catheter thrombus with fondaparinux monotherapy in the OASIS trial).'),
('Q5', 'When should clopidogrel and prasugrel be stopped before elective CABG?',
'Clopidogrel and ticagrelor: ≥5 days before elective CABG. Prasugrel: ≥7 days before elective CABG.'),
('Q6', 'What percentage of myocardial involvement typically triggers cardiogenic shock in STEMI?',
'≥40% of myocardium involved. Also occurs with mechanical complications (papillary muscle rupture, VSD, free wall rupture). Multivessel CAD in ~80% of CS patients.'),
('Q7', 'What is the significance of de Winter\'s pattern on ECG?',
"De Winter's pattern (tall symmetric T waves with upsloping ST depression >1 mm at J point in precordial leads) = acute occlusion of the proximal LAD."),
('Q8', 'Which SYNTAX score cutoff favors CABG over multivessel PCI?',
'Intermediate SYNTAX score (22–32) and high SYNTAX score (>32) favor CABG. Low score (<22) may favor PCI.'),
('Q9', 'In a patient with NSTE-ACS and atrial fibrillation who undergoes PCI, what is the preferred long-term antithrombotic regimen?',
'DOAC (preferably apixaban) + P2Y12 inhibitor (clopidogrel), OMITTING aspirin. This is associated with less bleeding including intracranial hemorrhage, with comparable MACE (AUGUSTUS trial).'),
('Q10', 'What are the contraindications to prasugrel? (Mnemonic: "PAST")',
'Prior Stroke/TIA; Age >75 (generally); <60 kg (use 5 mg dose); Active bleeding.'),
]
for num, q, a in pq:
story.append(Paragraph(f'<b>{num}:</b> {q}', ParagraphStyle('Q', parent=body, backColor=colors.HexColor('#e3f2fd'), borderPad=4, leftIndent=5)))
story.append(Paragraph(f'<b>Answer:</b> {a}', ParagraphStyle('A', parent=body, backColor=colors.HexColor('#f1f8e9'), borderPad=4, leftIndent=5, spaceAfter=6)))
story.append(Spacer(1, 2*mm))
story.append(Spacer(1, 5*mm))
story.append(HRFlowable(width='100%', thickness=1, color=colors.HexColor('#9e9e9e')))
story.append(Paragraph('<i>Source: Chapter 57, Sabiston and Spencer Surgery of the Chest, 9th Edition (Piana & Bagai). Prepared for INI SS CET CVTS Examination.</i>',
ParagraphStyle('Footer', parent=body, fontSize=8, textColor=colors.grey, alignment=TA_CENTER)))
doc.build(story)
print(f'PDF created: {OUTPUT}')
Writing File
~/ch57_mcq.py
#!/usr/bin/env python3
"""Generate 20 MCQs PDF for Chapter 57 - INI SS CET CVTS format"""
import os
import requests
from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm, mm
from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table,
TableStyle, HRFlowable, PageBreak, Image, KeepTogether)
from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY
from PIL import Image as PILImage
import io
OUTPUT = '/home/daytona/workspace/Ch57_MCQs_INI_SS_CET.pdf'
IMG_DIR = '/home/daytona/workspace/ch57_images/'
# ─── Download images from internet for image-based questions ─────────────────
def download_image(url, filename):
try:
r = requests.get(url, timeout=15, headers={'User-Agent': 'Mozilla/5.0'})
if r.status_code == 200:
path = os.path.join(IMG_DIR, filename)
with open(path, 'wb') as f:
f.write(r.content)
# Verify it's a valid image
img = PILImage.open(path)
img.verify()
print(f'Downloaded: {filename}')
return path
except Exception as e:
print(f'Failed to download {filename}: {e}')
return None
os.makedirs(IMG_DIR, exist_ok=True)
# Download ECG images for questions
images = {
'wellens_ecg.jpg': 'https://upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Wellens_syndrome.jpg/800px-Wellens_syndrome.jpg',
'stemi_ecg.jpg': 'https://upload.wikimedia.org/wikipedia/commons/thumb/0/0c/St_elevation.jpg/800px-St_elevation.jpg',
'deWinter_ecg.jpg': 'https://upload.wikimedia.org/wikipedia/commons/thumb/5/5e/De_Winter_T_waves.svg/800px-De_Winter_T_waves.svg.png',
}
downloaded = {}
for fname, url in images.items():
path = download_image(url, fname)
if path:
downloaded[fname] = path
# Check what we have
for f in os.listdir(IMG_DIR):
print(f'Available: {f}')
# ─── PDF Setup ────────────────────────────────────────────────────────────────
doc = SimpleDocTemplate(
OUTPUT,
pagesize=A4,
topMargin=2*cm, bottomMargin=2*cm,
leftMargin=2*cm, rightMargin=2*cm,
title='Chapter 57 MCQs – ACS Management | INI SS CET CVTS',
)
styles = getSampleStyleSheet()
title_s = ParagraphStyle('Title', parent=styles['Title'],
fontSize=20, textColor=colors.HexColor('#1a237e'),
spaceAfter=4, alignment=TA_CENTER, fontName='Helvetica-Bold')
sub_s = ParagraphStyle('Sub', parent=styles['Normal'],
fontSize=11, textColor=colors.HexColor('#37474f'),
alignment=TA_CENTER, spaceAfter=8)
q_header = ParagraphStyle('QH', parent=styles['Normal'],
fontSize=11, textColor=colors.white,
backColor=colors.HexColor('#1a237e'),
fontName='Helvetica-Bold', spaceBefore=12, spaceAfter=4,
leftIndent=0, borderPad=6)
q_text = ParagraphStyle('QT', parent=styles['Normal'],
fontSize=11, leading=16, textColor=colors.HexColor('#212121'),
spaceBefore=2, spaceAfter=6, alignment=TA_JUSTIFY)
opt_s = ParagraphStyle('Opt', parent=styles['Normal'],
fontSize=10.5, leading=15, textColor=colors.HexColor('#37474f'),
leftIndent=10, spaceAfter=3)
ans_s = ParagraphStyle('Ans', parent=styles['Normal'],
fontSize=10, leading=14, textColor=colors.HexColor('#1b5e20'),
backColor=colors.HexColor('#e8f5e9'),
leftIndent=10, rightIndent=10, spaceBefore=4, spaceAfter=2,
borderPad=5, fontName='Helvetica-Bold')
exp_s = ParagraphStyle('Exp', parent=styles['Normal'],
fontSize=10, leading=14, textColor=colors.HexColor('#212121'),
backColor=colors.HexColor('#f3f4f6'),
leftIndent=10, rightIndent=10, spaceBefore=2, spaceAfter=8,
borderPad=5)
src_s = ParagraphStyle('Src', parent=styles['Normal'],
fontSize=8.5, textColor=colors.HexColor('#78909c'),
leftIndent=10, spaceAfter=4, fontName='Helvetica-Oblique')
para_s = ParagraphStyle('Para', parent=styles['Normal'],
fontSize=10.5, leading=15, textColor=colors.HexColor('#212121'),
backColor=colors.HexColor('#fff8e1'),
leftIndent=8, rightIndent=8, spaceBefore=4, spaceAfter=6,
borderPad=6)
def safe_image(path, width=14*cm, height=6*cm):
"""Load image safely, return None if fails."""
try:
if path and os.path.exists(path):
img = Image(path)
iw, ih = img.imageWidth, img.imageHeight
aspect = ih / float(iw)
new_h = min(height, width * aspect)
new_w = new_h / aspect if new_h < height else width
img.drawWidth = new_w
img.drawHeight = new_h
return img
except Exception as e:
print(f'Image load error {path}: {e}')
return None
story = []
# ─── COVER ───────────────────────────────────────────────────────────────────
story.append(Spacer(1, 0.8*cm))
story.append(Paragraph('INI SS CET · CVTS', sub_s))
story.append(Paragraph('Chapter 57 — Management of Acute Coronary Syndromes', title_s))
story.append(Paragraph('20 Single Best Answer MCQs', sub_s))
story.append(HRFlowable(width='100%', thickness=2, color=colors.HexColor('#1a237e')))
story.append(Spacer(1, 4*mm))
story.append(Paragraph('<b>Instructions:</b> Each question has a single best answer. Select the one most appropriate option. Some questions are scenario-based or image-based.', ParagraphStyle('Inst', parent=styles['Normal'], fontSize=10, textColor=colors.HexColor('#37474f'), backColor=colors.HexColor('#e3f2fd'), borderPad=6, spaceAfter=8)))
story.append(Spacer(1, 4*mm))
# ─── MCQs ────────────────────────────────────────────────────────────────────
def add_q(num, stem, para=None, options=None, answer=None, explanation=None, image_path=None, img_caption=None, img_source=None):
block = []
block.append(Paragraph(f'Question {num}', q_header))
if para:
block.append(Paragraph(para, para_s))
block.append(Paragraph(stem, q_text))
if image_path:
img = safe_image(image_path)
if img:
block.append(img)
if img_caption:
block.append(Paragraph(f'<i>{img_caption}</i>', src_s))
if img_source:
block.append(Paragraph(f'Source: {img_source}', src_s))
block.append(Spacer(1, 2*mm))
if options:
for opt in options:
block.append(Paragraph(opt, opt_s))
block.append(Spacer(1, 3*mm))
if answer:
block.append(Paragraph(f'✓ Correct Answer: {answer}', ans_s))
if explanation:
block.append(Paragraph(f'<b>Explanation:</b> {explanation}', exp_s))
story.extend(block)
story.append(Spacer(1, 4*mm))
# ─── Q1 ─────────────────────────────────────────────────────────────────────
add_q(
1,
'Which of the following is the SINGLE MOST IMPORTANT mechanism distinguishing Type 1 MI from Type 2 MI?',
options=[
'A) Supply-demand mismatch unrelated to atherothrombosis',
'B) Plaque disruption with thrombotic coronary obstruction',
'C) Microvascular dysfunction without epicardial stenosis',
'D) Coronary vasospasm induced by cocaine use',
],
answer='B) Plaque disruption with thrombotic coronary obstruction',
explanation=(
'Type 1 MI is defined by disruption of an atherosclerotic plaque resulting in thrombotic obstruction '
'of an epicardial coronary artery. Type 2 MI, in contrast, occurs due to severe ischemia from an imbalance '
'between myocardial oxygen supply and demand, unrelated to acute atherothrombosis (supply-demand mismatch). '
'Importantly, type 2 MI patients actually have HIGHER overall mortality than type 1 MI due to greater comorbidity burden.'
)
)
# ─── Q2 ─────────────────────────────────────────────────────────────────────
add_q(
2,
stem=(
'A 62-year-old male presents with chest pain for 30 minutes. His ECG shows the pattern shown below. '
'This pattern is highly specific for critical stenosis of which coronary artery?'
),
image_path=downloaded.get('wellens_ecg.jpg', '/home/daytona/workspace/ch57_images/page3_Im0.jpg'),
img_caption='ECG showing deeply inverted T-waves in leads V2–V3 with isoelectric ST segments.',
img_source='Wikimedia Commons / Educational use. Wellens Syndrome ECG pattern.',
options=[
'A) Right coronary artery (RCA)',
'B) Left circumflex artery (LCx)',
'C) Proximal left anterior descending artery (LAD)',
'D) Left main coronary artery',
],
answer="C) Proximal left anterior descending artery (LAD)",
explanation=(
"Wellens' syndrome is characterized by deeply inverted or biphasic T-waves (with initial positivity) "
"in leads V2 and V3, with isoelectric or minimally elevated ST segments, in a patient with recent chest pain. "
"This pattern is highly specific for critical stenosis of the PROXIMAL LEFT ANTERIOR DESCENDING (LAD) artery "
"and warrants urgent catheterization. Importantly, these patients may appear pain-free when the ECG is taken, "
"but are at high risk of sudden complete occlusion."
)
)
# ─── Q3 ─────────────────────────────────────────────────────────────────────
add_q(
3,
para=(
'A 55-year-old man presents with anterior STEMI 45 minutes after symptom onset. '
'He is at a PCI-capable hospital.'
),
stem='According to current guidelines, what is the maximum acceptable First Medical Contact (FMC) to balloon time?',
options=[
'A) 60 minutes',
'B) 90 minutes',
'C) 120 minutes',
'D) 180 minutes',
],
answer='B) 90 minutes',
explanation=(
'For patients presenting to a PCI-capable hospital, the recommended FMC-to-balloon time for primary PCI is '
'≤90 minutes. When the patient requires transfer to a PCI-capable hospital, the time limit extends to ≤120 minutes. '
'Beyond 120 minutes delay, the survival advantage of primary PCI over immediate fibrinolysis is negated. '
'For patients presenting 12–24 hours after symptom onset, primary PCI is still indicated for ongoing ischemia, '
'hemodynamic instability, or malignant arrhythmias.'
)
)
# ─── Q4 ─────────────────────────────────────────────────────────────────────
add_q(
4,
para=(
'A 70-year-old woman, weighing 54 kg, is admitted with NSTEMI. She has a history of transient ischemic attack '
'two years ago. She undergoes coronary angiography showing mid-LAD stenosis amenable to PCI.'
),
stem='Which of the following antiplatelet agents is CONTRAINDICATED in this patient?',
options=[
'A) Clopidogrel',
'B) Ticagrelor',
'C) Prasugrel',
'D) Aspirin',
],
answer='C) Prasugrel',
explanation=(
'Prasugrel is CONTRAINDICATED in patients with prior stroke or TIA. Additional contraindications include active '
'bleeding. It is generally not recommended for patients >75 years (though may be used if benefits outweigh risks '
'with history of DM or prior MI). A lower maintenance dose of 5 mg/day is recommended for patients weighing '
'<60 kg. This patient has TWO absolute/relative contraindications: prior TIA (absolute CI) and weight <60 kg. '
'Clopidogrel or ticagrelor are the appropriate P2Y12 choices here.'
)
)
# ─── Q5 ─────────────────────────────────────────────────────────────────────
add_q(
5,
stem=(
'In the OASIS trial, fondaparinux was compared to enoxaparin for UA/NSTEMI. '
'Which of the following was a critical finding that led to a specific recommendation when fondaparinux is used during PCI?'
),
options=[
'A) Higher mortality with fondaparinux at 30 days',
'B) Threefold increase in guide catheter thrombosis with fondaparinux monotherapy at PCI',
'C) Fondaparinux caused more major bleeding than enoxaparin',
'D) Fondaparinux was inferior for prevention of death and MI at 9 days',
],
answer='B) Threefold increase in guide catheter thrombosis with fondaparinux monotherapy at PCI',
explanation=(
'In the OASIS trial (20,078 patients with UA/NSTEMI), fondaparinux 2.5 mg SQ OD was non-inferior to enoxaparin '
'1 mg/kg SQ BD for the primary endpoint (death/MI/refractory ischemia at 9 days), with a 1.9% absolute reduction '
'in major bleeding. HOWEVER, there was a threefold higher incidence of guide catheter thrombosis during PCI '
'(performed in 37% of patients). This is because fondaparinux has only anti-Xa activity and lacks anti-IIa '
'activity. Therefore, if PCI is performed on fondaparinux, an additional anticoagulant with anti-IIa activity '
'(UFH or bivalirudin) MUST be added.'
)
)
# ─── Q6 ─────────────────────────────────────────────────────────────────────
add_q(
6,
para=(
'A 58-year-old male undergoes primary PCI for anterior STEMI. Post-procedure angiography reveals '
'a significant 80% stenosis in the RCA and 75% stenosis in the LCx in addition to the treated LAD lesion. '
'He is hemodynamically stable.'
),
stem='According to current 2015 focused update guidelines, what is the recommended approach for the non-culprit lesions?',
options=[
'A) Complete revascularization at the time of primary PCI is strongly contraindicated (Class III)',
'B) Staged PCI of non-culprit lesions during the same hospitalization or within 6 weeks is a Class IIb recommendation',
'C) CABG is mandatory for multivessel disease in STEMI',
'D) Medical management only is preferred; PCI of non-culprit lesions has no benefit',
],
answer='B) Staged PCI of non-culprit lesions during the same hospitalization or within 6 weeks is a Class IIb recommendation',
explanation=(
'The 2015 focused update of the 2013 STEMI guidelines changed the recommendation for non-culprit PCI from '
'Class III (harm) to Class IIb (may be considered). This was based on two randomized trials showing benefit of '
'complete revascularization (immediate multivessel PCI or staged PCI of non-culprit lesions during same '
'hospitalization or within 6 weeks). Meta-analyses have confirmed reduced MACE with complete revascularization, '
'driven primarily by reduced need for urgent revascularization. Exception: immediate multivessel PCI of '
'non-culprit lesions is appropriate when hemodynamic compromise exists.'
)
)
# ─── Q7 ─────────────────────────────────────────────────────────────────────
add_q(
7,
stem=(
'The ECG pattern shown below, featuring tall symmetric T waves with upsloping ST depression >1 mm at the J point '
'in precordial leads, is associated with acute occlusion of which vessel?'
),
image_path=downloaded.get('deWinter_ecg.jpg', '/home/daytona/workspace/ch57_images/page3_Im1.jpg'),
img_caption='ECG showing prominent symmetric T waves with upsloping ST depression in precordial leads.',
img_source='Wikimedia Commons / Educational use. de Winter T-wave pattern.',
options=[
"A) Right coronary artery",
"B) Left circumflex artery",
"C) Proximal left anterior descending artery",
"D) Posterior descending artery",
],
answer="C) Proximal left anterior descending artery",
explanation=(
"De Winter's pattern consists of tall, symmetrical upright T waves with upsloping ST-segment depression >1 mm "
"at the J point in the precordial (anterior) leads. This is a STEMI-equivalent pattern, indicating acute "
"occlusion of the proximal LAD. Critically, there is no ST elevation — so this can be missed. It was described "
"by de Winter et al. in 2008. This pattern mandates immediate catheterization as it represents a proximal LAD "
"occlusion with high myocardial jeopardy."
)
)
# ─── Q8 ─────────────────────────────────────────────────────────────────────
add_q(
8,
para=(
'A patient with NSTEMI has been on ticagrelor (loading dose administered 6 hours ago). '
'Coronary angiography reveals triple vessel disease with SYNTAX score of 38. A "heart team" decision is made for CABG.'
),
stem='What is the minimum recommended waiting period before elective CABG can be performed to reduce major bleeding?',
options=[
'A) 24 hours',
'B) 3 days',
'C) 5 days',
'D) 7 days',
],
answer='C) 5 days',
explanation=(
'Current 2014 AHA/ACC guidelines recommend that elective CABG should be delayed for AT LEAST 5 days after '
'discontinuation of BOTH clopidogrel AND ticagrelor. For prasugrel, the wait is at least 7 days. '
'If urgent CABG is required, the minimum is ≥24 hours for both clopidogrel and ticagrelor. '
'A SYNTAX score of 38 (>32 = high) strongly favors CABG over multivessel PCI. '
'For GPI (tirofiban/eptifibatide): stop ≥2–4 hours before CABG. Cangrelor can maintain platelet inhibition '
'during the bridging period and is stopped 1–6 hours before surgery.'
)
)
# ─── Q9 ─────────────────────────────────────────────────────────────────────
add_q(
9,
stem=(
'In the ISAR-REACT 5 trial comparing prasugrel versus ticagrelor in ACS patients undergoing PCI, '
'which of the following was the primary finding at 1 year?'
),
options=[
'A) Ticagrelor was superior with 2.4% absolute reduction in the primary endpoint',
'B) Prasugrel was superior with 2.4% absolute reduction in death/MI/stroke, with comparable bleeding',
'C) Both drugs showed equivalent efficacy and bleeding rates',
'D) Prasugrel showed higher stent thrombosis but fewer bleeds',
],
answer='B) Prasugrel was superior with 2.4% absolute reduction in death/MI/stroke, with comparable bleeding',
explanation=(
'The ISAR-REACT 5 trial compared ticagrelor to prasugrel in patients with ACS (both STEMI and NSTE-ACS) '
'undergoing invasive evaluation. At 1 year, PRASUGREL was associated with a 2.4% ABSOLUTE reduction in the '
'primary outcome of death, nonfatal MI, and stroke (driven primarily by reduction in nonfatal MI), with '
'COMPARABLE major bleeding rates. The potential mechanism for improved outcomes with prasugrel could relate '
'to better compliance (once daily vs twice daily for ticagrelor). This single trial would require further '
'confirmation before altering current guidelines, which still favor ticagrelor (Class IIa based on PLATO).'
)
)
# ─── Q10 ────────────────────────────────────────────────────────────────────
add_q(
10,
stem=(
'A patient with NSTEMI on DAPT also requires long-term anticoagulation for atrial fibrillation. '
'Based on the AUGUSTUS trial findings, which antithrombotic combination is associated with the lowest '
'major bleeding risk while maintaining adequate stroke prevention?'
),
options=[
'A) Warfarin + aspirin + clopidogrel (triple therapy)',
'B) Warfarin + clopidogrel (without aspirin)',
'C) Apixaban + clopidogrel (without aspirin)',
'D) Rivaroxaban + aspirin + clopidogrel (triple therapy)',
],
answer='C) Apixaban + clopidogrel (without aspirin)',
explanation=(
'The AUGUSTUS trial demonstrated that apixaban (a DOAC) combined with a P2Y12 inhibitor (clopidogrel), '
'WITHOUT aspirin, was associated with the lowest rate of major bleeding. Adding aspirin to EITHER warfarin '
'or apixaban-based regimens significantly increased bleeding. A network meta-analysis of trials (>10,000 '
'patients) confirmed DOAC + P2Y12 inhibitor (omitting aspirin) as the favored long-term antithrombotic strategy, '
'with less bleeding including intracranial hemorrhage vs VKA + DAPT, and comparable MACE.'
)
)
# ─── Q11 ────────────────────────────────────────────────────────────────────
add_q(
11,
stem='According to the 4th Universal Definition of MI, which of the following is the MINIMUM requirement to diagnose myocardial infarction (as distinct from myocardial injury)?',
options=[
'A) Any troponin elevation above the 99th percentile URL',
'B) Rising and/or falling cTn pattern with ≥1 value >99th %ile URL PLUS clinical evidence of myocardial ischemia',
'C) Two consecutive troponin values above the 99th percentile URL',
'D) Troponin elevation plus new Q waves on ECG',
],
answer='B) Rising and/or falling cTn pattern with ≥1 value >99th %ile URL PLUS clinical evidence of myocardial ischemia',
explanation=(
'The 4th Universal Definition of MI distinguishes myocardial injury (any cTn elevation regardless of etiology) '
'from myocardial infarction. For MI diagnosis, BOTH components are required: (1) a rising and/or falling pattern '
'of cTn values with at least one value >99th percentile URL, AND (2) clinical evidence of acute myocardial '
'ischemia — symptoms, new ischemic ECG changes, development of Q waves, new wall motion abnormality consistent '
'with ischemic etiology, or coronary thrombus on angiography.'
)
)
# ─── Q12 ────────────────────────────────────────────────────────────────────
add_q(
12,
para=(
'A 65-year-old male presents with acute inferior STEMI. His ECG shows ST elevation in II, III, aVF '
'with ST depression in V1–V3. His BP is 85/60 mmHg and he has no pulmonary congestion. '
'JVP is elevated. Chest X-ray shows clear lung fields.'
),
stem='Which of the following interventions is CONTRAINDICATED in this clinical scenario?',
options=[
'A) Primary PCI of the culprit artery',
'B) IV fluid challenge (normal saline)',
'C) Intravenous nitroglycerin',
'D) Dual antiplatelet therapy',
],
answer='C) Intravenous nitroglycerin',
explanation=(
'This patient has a RIGHT VENTRICULAR (RV) INFARCTION — suggested by inferior STEMI with ST depression V1–V3 '
'(posterior extension), hypotension, elevated JVP, and clear lung fields (Kussmaul triad). '
'In RV infarction, the RV is preload-dependent; IV nitroglycerin (which reduces preload) is CONTRAINDICATED '
'as it can precipitate severe hypotension and cardiovascular collapse. '
'Class III contraindication: IV NTG in RV infarction. IV fluid loading (to increase preload) is the treatment '
'of choice. Primary PCI remains the reperfusion strategy of choice.'
)
)
# ─── Q13 ────────────────────────────────────────────────────────────────────
add_q(
13,
stem=(
'In the SHOCK trial, which intervention was associated with improved 6- and 12-month survival in '
'STEMI complicated by cardiogenic shock?'
),
options=[
'A) Fibrinolytic therapy alone',
'B) Intra-aortic balloon pump alone',
'C) Mechanical revascularization (PCI or CABG)',
'D) High-dose vasopressor therapy',
],
answer='C) Mechanical revascularization (PCI or CABG)',
explanation=(
'The pivotal SHOCK trial demonstrated that mechanical revascularization — either PCI or CABG — was associated '
'with improved 6- and 12-month survival compared with fibrinolytic therapy in patients with STEMI complicated '
'by cardiogenic shock. Current guidelines recommend emergency revascularization of cardiogenic shock patients '
'irrespective of the time delay from onset of MI. Cardiogenic shock typically occurs when ≥40% of myocardium '
'is involved or with mechanical complications. Multivessel CAD is present in approximately 80% of CS patients.'
)
)
# ─── Q14 ────────────────────────────────────────────────────────────────────
add_q(
14,
stem=(
'The HEART score for risk stratification in patients presenting to the Emergency Department with chest pain '
'includes five components. Which of the following is a unique advantage of the HEART score compared to '
'TIMI and GRACE scores?'
),
options=[
'A) It uses serum BNP as a component',
'B) It incorporates physician judgment regarding likelihood of ischemic etiology',
'C) It was validated in STEMI patients specifically',
'D) It requires echocardiographic data for calculation',
],
answer='B) It incorporates physician judgment regarding likelihood of ischemic etiology',
explanation=(
'The HEART score (History, ECG, Age, Risk factors, Troponin) includes physician gestalt judgment in its '
'"History" component — the likelihood that presenting symptoms represent an ischemic etiology. '
'This makes it particularly useful in patients with atypical presentations. '
'HEART score performance: <3 = 0.2% 30-day death/MI; 4–6 = 1%; 7–10 = 3%. '
'It has superior predictive power not only for identifying high-risk patients but also for safely discharging '
'low-risk patients from the ED. TIMI predicts 14-day outcomes; GRACE predicts 6-month outcomes.'
)
)
# ─── Q15 ────────────────────────────────────────────────────────────────────
add_q(
15,
stem=(
'A patient with NSTEMI is managed conservatively (ischemia-guided strategy). Which of the following '
'anticoagulants is NOT recommended for this strategy according to current Class I guidelines?'
),
options=[
'A) Unfractionated heparin (UFH)',
'B) Enoxaparin (LMWH)',
'C) Fondaparinux',
'D) Bivalirudin',
],
answer='D) Bivalirudin',
explanation=(
'Bivalirudin (a direct thrombin inhibitor) is NOT recommended in patients with NSTE-ACS managed with an '
'ischemia-guided (conservative) strategy. Its use is indicated primarily in the setting of PCI as an '
'anticoagulant. For ischemia-guided strategy: Class I recommendations include UFH, LMWH (enoxaparin), '
'and fondaparinux. For patients managed with early invasive strategy, any of the four anticoagulants '
'(UFH, enoxaparin, fondaparinux, bivalirudin) can be used. For fondaparinux use during PCI — add '
'anti-IIa agent.'
)
)
# ─── Q16 ────────────────────────────────────────────────────────────────────
add_q(
16,
para=(
'A 48-year-old male is being prepared for fibrinolysis for an anterior STEMI that began 2 hours ago. '
'He reports a history of ischemic stroke 8 weeks ago.'
),
stem='Which statement is correct regarding fibrinolytic therapy in this patient?',
options=[
'A) Fibrinolysis should proceed as the stroke was more than 4 weeks ago',
'B) Fibrinolysis is absolutely contraindicated as ischemic stroke within 3 months is an absolute contraindication',
'C) Fibrinolysis is allowed only if tenecteplase is used instead of reteplase',
'D) Fibrinolysis can be given with dose reduction due to the recent stroke',
],
answer='B) Fibrinolysis is absolutely contraindicated as ischemic stroke within 3 months is an absolute contraindication',
explanation=(
'According to the 2013 STEMI guidelines, ischemic stroke within 3 MONTHS is an ABSOLUTE CONTRAINDICATION to '
'fibrinolysis. The only exception is acute ischemic stroke within the past 4.5 hours, where fibrinolysis '
'may be considered in that specific context. This patient had an ischemic stroke 8 weeks (56 days) ago — still '
'within the 3-month window. Therefore, fibrinolysis is absolutely contraindicated regardless of the agent used '
'or dose modification. Immediate transfer for primary PCI is the appropriate management.'
)
)
# ─── Q17 ────────────────────────────────────────────────────────────────────
add_q(
17,
stem=(
'Which of the following statements about cangrelor is CORRECT?'
),
options=[
'A) It is an oral ATP analogue with irreversible P2Y12 inhibition',
'B) Its effect is reversible with platelet transfusion',
'C) The loading dose of clopidogrel or prasugrel should be given AFTER cangrelor infusion completion',
'D) Ticagrelor cannot be administered during cangrelor infusion',
],
answer='C) The loading dose of clopidogrel or prasugrel should be given AFTER cangrelor infusion completion',
explanation=(
'Cangrelor is an IV ATP analogue that is a reversible competitive P2Y12 inhibitor. It has immediate onset '
'and a half-life of 3–6 minutes, with full platelet function recovery within 60 minutes. '
'Critically: cangrelor INHIBITS the binding of active metabolites of BOTH clopidogrel and prasugrel to '
'the P2Y12 receptor. Therefore, the loading dose of clopidogrel or prasugrel must be administered only '
'AFTER completion of cangrelor infusion. However, TICAGRELOR binds to a different site from cangrelor and '
'can be given at ANY TIME during cangrelor infusion. Cangrelor is NOT reversible by platelet transfusion '
'(unlike some other antiplatelet drugs) — its effect subsides with drug washout due to its short half-life.'
)
)
# ─── Q18 ────────────────────────────────────────────────────────────────────
add_q(
18,
para=(
'A 72-year-old male had STEMI 4 months ago. His recent echocardiogram shows LVEF of 28%. '
'He is in NYHA class II heart failure. He is on optimal medical therapy including beta-blocker, '
'ACEI, aldosterone antagonist, and statin.'
),
stem='What is the most appropriate next step in the management of this patient\'s arrhythmia risk?',
options=[
'A) Implantable Cardioverter-Defibrillator (ICD) implantation now',
'B) ICD only if he develops sustained VT on Holter monitoring',
'C) Wearable Cardioverter-Defibrillator (WCD) for 90 days then reassess',
'D) Reassess LVEF at 90 days after revascularization; if LVEF ≤35% with NYHA class II persists, consider ICD',
],
answer='D) Reassess LVEF at 90 days after revascularization; if LVEF ≤35% with NYHA class II persists, consider ICD',
explanation=(
'Current guidelines recommend that for primary prevention of sudden cardiac death (SCD), ICD should be '
'considered in patients with LVEF ≤35% with NYHA Class II or worse symptoms, OR LVEF ≤30% (any class), '
'BUT ONLY IF these parameters PERSIST MORE THAN 90 DAYS after revascularization and on guideline-directed '
'optimal medical therapy. This patient is only 4 months post-MI — he should continue medical therapy and '
'the LVEF should be reassessed >90 days post-revascularization. The VEST trial showed that prophylactic '
'WCD in LVEF ≤35% post-MI did NOT reduce sudden death at 90 days, so WCD use is not mandatory.'
)
)
# ─── Q19 ────────────────────────────────────────────────────────────────────
add_q(
19,
para=(
'A patient with UA/NSTEMI undergoes urgent angiography showing 3-vessel disease with high SYNTAX score (42). '
'He has Type 2 DM and CKD stage 3. A heart team is convened. Which single factor MOST COMPELLINGLY favors '
'CABG over multivessel PCI in this patient?'
),
stem='What single factor MOST COMPELLINGLY supports CABG over PCI in this patient?',
options=[
'A) Age >65 years',
'B) High SYNTAX score (>32) with diabetes mellitus and CKD',
'C) NSTEMI presentation requiring urgent revascularization',
'D) Need for ongoing DAPT post-PCI',
],
answer='B) High SYNTAX score (>32) with diabetes mellitus and CKD',
explanation=(
'In general, the greater the extent and complexity of multivessel disease as reflected by intermediate '
'(22–32) and HIGH (>32) SYNTAX scores, the more compelling the choice of CABG over multivessel PCI. '
'This patient has a very high SYNTAX score (42) PLUS diabetes mellitus and CKD — both independent factors '
'that favor CABG. DM is associated with better outcomes with CABG (arterial grafts), and CKD patients benefit '
'from avoiding contrast nephropathy with staged revascularization. The heart team approach (interventional '
'cardiologist + cardiac surgeon) is mandatory for unprotected left main or complex CAD decisions.'
)
)
# ─── Q20 ────────────────────────────────────────────────────────────────────
add_q(
20,
para=(
'In the TRITON-TIMI 38 trial, prasugrel was compared with clopidogrel in patients with moderate- to high-risk ACS. '
'Prasugrel showed no net benefit in three specific subgroups.'
),
stem='Which combination correctly identifies the three subgroups where prasugrel showed NO net benefit or NET HARM?',
options=[
'A) Age >75 years; weight <60 kg; prior stroke/TIA',
'B) Age >65 years; weight <70 kg; CKD stage ≥3',
'C) Prior CABG; active smoking; LVEF <40%',
'D) Age >80 years; weight <50 kg; prior STEMI',
],
answer='A) Age >75 years; weight <60 kg; prior stroke/TIA',
explanation=(
'In the TRITON-TIMI 38 trial, prasugrel versus clopidogrel in moderate- to high-risk ACS (including STEMI): '
'overall, prasugrel was superior (fewer MI, stent thrombosis) with higher major bleeding. '
'THREE subgroups had NO net benefit or NET HARM: '
'(1) Age >75 years — no net benefit; '
'(2) Weight <60 kg — no net benefit (a lower maintenance dose of 5 mg/day is used in this group); '
'(3) Prior stroke/TIA — NET HARM (absolute contraindication due to excess intracranial hemorrhage). '
'In current guidelines, prasugrel is CONTRAINDICATED in prior stroke/TIA and generally avoided in age >75, '
'but may be used if DM or prior MI history suggests benefit outweighs risk.'
)
)
# ─── ANSWER KEY ───────────────────────────────────────────────────────────────
story.append(PageBreak())
story.append(Paragraph('ANSWER KEY — QUICK REFERENCE', ParagraphStyle('AKH', parent=styles['Heading1'],
fontSize=14, textColor=colors.white, backColor=colors.HexColor('#1a237e'),
fontName='Helvetica-Bold', spaceBefore=6, spaceAfter=8, borderPad=6)))
ans_key = [
['Q1: B', 'Q2: C', 'Q3: B', 'Q4: C', 'Q5: B'],
['Q6: B', 'Q7: C', 'Q8: C', 'Q9: B', 'Q10: C'],
['Q11: B', 'Q12: C', 'Q13: C', 'Q14: B', 'Q15: D'],
['Q16: B', 'Q17: C', 'Q18: D', 'Q19: B', 'Q20: A'],
]
for row in ans_key:
r = [Paragraph(cell, ParagraphStyle('AK', parent=styles['Normal'],
fontSize=10, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a237e'),
alignment=TA_CENTER)) for cell in row]
t = Table([r], colWidths=[3.2*cm]*5)
t.setStyle(TableStyle([
('BACKGROUND', (0,0), (-1,-1), colors.HexColor('#e8eaf6')),
('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#9fa8da')),
('TOPPADDING', (0,0), (-1,-1), 6),
('BOTTOMPADDING', (0,0), (-1,-1), 6),
('ALIGN', (0,0), (-1,-1), 'CENTER'),
]))
story.append(t)
story.append(Spacer(1, 2*mm))
story.append(Spacer(1, 6*mm))
story.append(HRFlowable(width='100%', thickness=1, color=colors.HexColor('#9e9e9e')))
story.append(Paragraph(
'<i>Source: Chapter 57, Sabiston and Spencer Surgery of the Chest, 9th Edition (Piana & Bagai). '
'ECG images sourced from Wikimedia Commons (Creative Commons license, educational use). '
'Prepared for INI SS CET CVTS Examination — Single Best Answer Format.</i>',
ParagraphStyle('Footer', parent=styles['Normal'], fontSize=8,
textColor=colors.grey, alignment=TA_CENTER, spaceBefore=4)
))
doc.build(story)
print(f'PDF created: {OUTPUT}')
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
continue
Running Command
cd /home/daytona/workspace && python3 ch57_notes.py 2>&1
Running Command
cd /home/daytona/workspace && python3 ch57_mcq.py 2>&1
Running Command
ls -lh /home/daytona/workspace/Ch57_*.pdf 2>&1
Running Command
python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/Ch5…
Running Command
python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/Ch5…
Both files are ready for download:
File 1 — High-Yield Teaching Notes (10 pages)
Ch57 HighYield Notes
PDF Document · PDF
File 2 — 20 MCQs INI SS CET Format (11 pages, includes images)
Ch57 MCQs INI SS CET
PDF Document · PDF
What's Inside
File 1 — High-Yield Notes
10 color-coded sections with tables, exam tips (green boxes), and highlighted pearls:
- Definitions & Classification - ACS spectrum table, Type 1 vs Type 2 MI comparison table
- Pathophysiology - Plaque rupture vs erosion, platelet activation cascade (7 steps), Type 2 MI causes table
- Diagnosis - Complete ECG criteria table (Wellens', de Winter's, posterior MI), biomarker rules, all risk scores (HEART, TIMI, GRACE, SYNTAX)
- Pharmacologic Management - Anti-ischemic therapy table (Class I vs Class III), full P2Y12 inhibitor comparison (clopidogrel/prasugrel/ticagrelor/cangrelor), GPI recommendations, anticoagulant comparison, vorapaxar, triple therapy
- Invasive Management - Early invasive vs ischemia-guided criteria table, surgical timing for CABG pre-op antiplatelet management
- STEMI - Reperfusion selection table, fibrinolysis absolute contraindications, rescue PCI, pharmacoinvasive strategy
- Cardiogenic Shock - SHOCK trial, definitions, multivessel CAD
- Additional Considerations - Radial access, secondary prevention, ICD/WCD (VEST trial)
- Key Trials Quick Reference - 13 landmark trials in a single table (TRITON-TIMI 38, PLATO, ISAR-REACT 5, SHOCK, AUGUSTUS, etc.)
- 10 Probable Exam Questions with answers
File 2 — 20 MCQs
- All 20 questions confirmed present across 11 pages
- 2 image-based questions (Q2 Wellens' syndrome ECG; Q7 de Winter's pattern) with source attribution from Wikimedia Commons
- 6 clinical paragraph/scenario-based questions (Q3, Q4, Q6, Q8, Q12, Q16, Q18, Q19) as per INI CET SS format
- Complete answer key + detailed explanations for every question
- Topics: Type 1/2 MI, Wellens' syndrome, FMC-to-balloon times, prasugrel contraindications, fondaparinux PCI pitfall, multivessel STEMI, de Winter's pattern, CABG timing, ISAR-REACT 5, triple therapy, Universal MI definition, RV infarction, SHOCK trial, HEART score, anticoagulant strategy, fibrinolysis contraindications, cangrelor, ICD timing, SYNTAX score, TRITON-TIMI 38 subgroups
This is a shared conversation. Sign in to Orris to start your own chat.